BACKGROUND: Mutations involving the oncogene K-ras in colorectal cancer may be related to tumor aggressiveness. However, the value of K-ras gene determination as a prognostic marker has not been clearly established. PATIENTS AND METHODS: The results from 98 patients recruited in a prospective study analyzing the effect of a K-ras mutation as a prognostic factor in colorectal cancer are reported. RESULTS: Disease-free (P = 0.02) and overall survival (P = 0.03) were significantly reduced for patients harboring a K-ras mutation. Two specific mutations demonstrated a significantly increased risk of disease recurrence, namely, 12-TGT (P = 0.04) and 13-GAC substitutions (P = 0.002). Patients with either of these substitutions had a 2-year disease-free survival rate of 37% compared with that of 67% for the group of patients harboring any other mutation type or a wild-type status (P = 0.01). CONCLUSIONS: The results herein presented suggest that K-ras acts as a prognostic factor in colorectal cancer and that this effect is probably related to a limited number of defined mutations.
BACKGROUND: Mutations involving the oncogene K-ras in colorectal cancer may be related to tumor aggressiveness. However, the value of K-ras gene determination as a prognostic marker has not been clearly established. PATIENTS AND METHODS: The results from 98 patients recruited in a prospective study analyzing the effect of a K-ras mutation as a prognostic factor in colorectal cancer are reported. RESULTS: Disease-free (P = 0.02) and overall survival (P = 0.03) were significantly reduced for patients harboring a K-ras mutation. Two specific mutations demonstrated a significantly increased risk of disease recurrence, namely, 12-TGT (P = 0.04) and 13-GAC substitutions (P = 0.002). Patients with either of these substitutions had a 2-year disease-free survival rate of 37% compared with that of 67% for the group of patients harboring any other mutation type or a wild-type status (P = 0.01). CONCLUSIONS: The results herein presented suggest that K-ras acts as a prognostic factor in colorectal cancer and that this effect is probably related to a limited number of defined mutations.
Authors: Mariana Petaccia Macedo; Louise De Brot Andrade; Renata Coudry; Rodrigo Crespo; Marina Gomes; Bianca Cristina Garcia Lisboa; Samuel Aguiar; Fernando Augusto Soares; Dirce Maria Carraro; Isabela Werneck Cunha Journal: Int J Colorectal Dis Date: 2011-05-21 Impact factor: 2.571
Authors: W S Samowitz; J A Holden; K Curtin; S L Edwards; A R Walker; H A Lin; M A Robertson; M F Nichols; K M Gruenthal; B J Lynch; M F Leppert; M L Slattery Journal: Am J Pathol Date: 2001-04 Impact factor: 4.307
Authors: Nakul P Valsangkar; Thun Ingkakul; Camilo Correa-Gallego; Mari Mino-Kenudson; Ricard Masia; Keith D Lillemoe; Carlos Fernández-del Castillo; Andrew L Warshaw; Andrew S Liss; Sarah P Thayer Journal: Surgery Date: 2015-02 Impact factor: 3.982
Authors: V Deschoolmeester; C Boeckx; M Baay; J Weyler; W Wuyts; E Van Marck; M Peeters; F Lardon; J B Vermorken Journal: Br J Cancer Date: 2010-10-19 Impact factor: 7.640
Authors: Jens K Habermann; Franz G Bader; Christian Franke; Kaja Zimmermann; Timo Gemoll; Britta Fritzsche; Thomas Ried; Gert Auer; Hans-Peter Bruch; Uwe J Roblick Journal: Langenbecks Arch Surg Date: 2007-10-16 Impact factor: 3.445